

Bariatric surgery: new indications and metabolic outcomes

Patricio Xavier Duran Saraguro

Bariatric Surgery: New Indications and Metabolic Outcomes

Patricio Xavier Duran Saraguro

IMPORTANT

The information presented here is not intended to replace professional advice in crisis or emergency situations. For the diagnosis and management of any particular condition, it is recommended that you consult a certified professional.

Each of the articles compiled here is the sole responsibility of its authors.

ISBN: 978-9942-568-58-8

A production © Cuevas Editores SAS

June 2025

Av. República del Salvador, Edificio TerraSol 7-2

Quito, Ecuador

www.cuevaseditores.com

Published in Ecuador

Any form of reproduction, distribution, public communication, or transformation of this work may only be carried out with the authorization of its owners, except as provided by law.

3

Bariatric Surgery: New Indications and Metabolic Outcomes

Patricio Xavier Duran Saraguro

Médico Residente Ministerio de Salud Pública Cuenca, Ecuador

Definition

Bariatric surgery refers to a range of surgical procedures performed on individuals with obesity with the primary goal of inducing significant and sustainable weight loss and improving obesity-related comorbidities. These procedures typically work by altering the gastrointestinal tract to restrict food intake, reduce nutrient absorption, or both.

Brief Description of the Procedure, Including What It Entails and When It Is Performed

Bariatric surgical procedures involve modifying the stomach and/or small intestine to limit food intake, reduce calorie absorption, or alter gut hormone signaling. They are typically performed when conventional weight loss methods (diet, exercise, behavioral therapy) have been unsuccessful for individuals with severe obesity (Body Mass Index - BMI of 40 kg/m\$^2\$ or higher) or those with a BMI of 35-39.9 kg/m\$^2\$ who also suffer from significant obesity-related comorbidities. The timing of the surgery is usually after a thorough multidisciplinary evaluation, including psychological, nutritional, and medical assessments to ensure patient readiness and suitability.

Indications

Bariatric surgery is recommended for individuals meeting specific criteria, primarily related to their BMI and the presence of obesity-related comorbidities.

Medical conditions or situations in which the procedure is recommended:

- Class III Obesity: BMI $\geq 40 \text{ kg/m}$ \$\text{\$\gamma}2\$\$
- Class II Obesity with Co-morbidities: BMI of 35-39.9 kg/m\$^2\$ with at least one significant obesity-related comorbidity such as
- Type 2 Diabetes Mellitus (T2DM)
- Hypertension
- Dyslipidemia
- Obstructive Sleep Apnea
- Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)
- Osteoarthritis
- Gastroesophageal Reflux Disease (GERD)
- Certain types of cancer
- **Emerging Indications:** There is increasing interest in bariatric surgery for individuals with lower BMIs (e.g., 30-34.9 kg/m\$^2\$) who have poorly controlled T2DM, even without severe obesity, given the significant metabolic benefits of these procedures.

Classification

Bariatric surgical procedures can be broadly classified based on their primary mechanism of action:

- **Restrictive Procedures:** Primarily limit food intake by reducing stomach size.
- **Sleeve Gastrectomy (SG):** A large portion of the stomach is removed, creating a smaller, tube-shaped stomach.
- Malabsorptive Procedures: Primarily reduce nutrient absorption by bypassing a portion of the small intestine. (Purely malabsorptive procedures are rarely performed due to significant nutritional deficiencies).

- Combined Restrictive and Malabsorptive Procedures: Incorporate both mechanisms.
- Roux-en-Y Gastric Bypass (RYGB): A small stomach pouch is created, and a section of the small intestine is bypassed and connected to this pouch.
- One Anastomosis Gastric Bypass (OAGB) / Mini-Gastric Bypass (MGB): A longer, narrower stomach pouch is created, and a loop of small intestine is connected to it.
- Biliopancreatic Diversion with Duodenal Switch (BPD/DS): A more aggressive procedure involving a sleeve gastrectomy and a significant bypass of the small intestine.

Epidemiology

To provide the most accurate and recent epidemiological data, I will search for the prevalence of obesity and bariatric surgery in North America, Europe, or globally through the WHO, as specific data for Ecuador might be limited or less recent. Epidemiology:

Prevalence of Obesity: Obesity is a global epidemic, with increasing prevalence across all regions. According to the WHO, in 2022, 1 in 8 people worldwide were living with obesity. The global prevalence of adult obesity more than doubled between 1990 and 2022, with 890 million adults living with obesity in 2022. The prevalence of overweight and obesity varies significantly by region. For instance, in 2022, the prevalence of overweight was highest in the WHO Region of the Americas (67%) compared to the WHO South-East Asia Region and the African Region (31%) [1].

In North America, particularly the United States, obesity rates are significantly higher than in Europe. In the U.S., some states report obesity rates exceeding 30%, with some surpassing 40%. Conversely, in most European countries, obesity rates remain below 25%, with some Southern and Western European nations reporting levels under 15% [2]. However, the problem is growing in

Europe as well, with many countries approaching or exceeding 20% obesity rates, particularly in Eastern and Northern Europe [3]. For example, the WHO European Region reported in 2022 that almost 60% of adults and nearly one in three children are living with overweight or obesity [4].

For Ecuador, based on data from the Global Obesity Observatory, the percentage of adults with obesity (BMI \geq 30) in Ecuador was 29.63% [5].

Bariatric Surgery Rates: Despite the high prevalence of obesity, only a small percentage of eligible individuals undergo bariatric surgery. Globally, it's estimated that only 1-2% of eligible patients proceed with the surgery [6].

The number of bariatric surgeries performed globally is increasing. According to the IFSO (International Federation for the Surgery of Obesity and Metabolic Disorders) Worldwide Survey 2020-2021, the total number of surgical and endoluminal procedures performed was 507,806 in 2020 and 598,834 in 2021. Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) remain the most common procedures worldwide. For example, in 2021, SG accounted for 351,689 procedures and RYGB for 159,543 procedures globally [7].

In North America, the United States performs the highest number of bariatric surgeries. In 2023, an estimated 157,254 sleeve gastrectomies and 63,132 Roux-en-Y gastric bypasses were performed in the US [8]. The bariatric surgeries market in North America led with a substantial revenue share in 2023, followed by Europe [9]. In Europe, countries like France and Germany have seen a significant increase in bariatric surgery numbers [10]. Sweden is a leader in obesity surgery, with 9 surgeries performed per 10,000 residents [10].

Surgical Technique

This section will provide a detailed description of the procedures, focusing on the most common ones: Sleeve Gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB).

Preoperative Preparation (General for all Bariatric Procedures):

- **Multidisciplinary Evaluation**: Patients undergo comprehensive assessment by a team including a bariatric surgeon, dietitian, psychologist/psychiatrist, endocrinologist, and other specialists as needed. This evaluates medical readiness, addresses psychological factors, and ensures understanding of lifestyle changes.
- **Nutritional Optimization:** Patients are typically required to follow a specific pre-operative diet (often liquid or low-calorie) for several weeks to reduce liver size and abdominal fat, making the surgery safer.
- **Smoking Cessation:** Complete cessation of smoking is mandatory several weeks prior to surgery due to increased risk of complications.
- **Medication Review:** Adjustment or discontinuation of certain medications (e.g., anticoagulants, diabetes medications) is necessary.
- **Informed Consent:** Detailed discussion of risks, benefits, and alternatives with the patient.

Procedural Steps:

1. Laparoscopic Sleeve Gastrectomy (LSG):

- **Anesthesia**: General anesthesia is administered.
- **Incision:** Typically performed laparoscopically, involving several small incisions (5-12 mm) in the abdomen.

- **Trocar Placement:** Ports are inserted through these incisions to allow insertion of instruments and a camera.
- **Stomach Mobilization:** The greater curvature of the stomach is dissected free from the omentum and surrounding attachments from the pylorus to the angle of His.
- Calibration Tube Insertion: A calibration tube (bougie) is inserted into the stomach via the mouth and guided into the pylorus. This serves as a guide for the stapler.
- **Gastric Resection:** Using linear staplers, the stomach is divided vertically alongside the bougie, removing approximately 75-85% of the stomach. The resected portion is removed from the abdomen.
- **Leak Test:** The staple line is typically checked for leaks using an air leak test or methylene blue dye.
- **Drain Placement (Optional):** A drain may be placed near the staple line to monitor for leaks.
- **Closure:** Incisions are closed with sutures or staples.

2. Laparoscopic Roux-en-Y Gastric Bypass (LRYGB):

- **Anesthesia**: General anesthesia is administered.
- **Incision:** Performed laparoscopically with several small incisions.
- **Trocar Placement:** Ports are inserted for instruments and camera.
- **Creation of Gastric Pouch**: The stomach is divided to create a small (30-50 mL) upper gastric pouch, completely separating it from the rest of the stomach.
- Roux Limb Creation (Jejunojejunostomy): The jejunum is divided approximately 50-70 cm distal to the Ligament of Treitz. The distal

segment (Roux limb) is brought up and connected to the newly created gastric pouch (gastrojejunostomy).

- Biliopancreatic Limb Creation (Jejunojejunostomy): The proximal segment of the divided jejunum (biliopancreatic limb), which carries digestive enzymes and bile, is reconnected to the Roux limb approximately 75–150 cm downstream from the gastrojejunostomy. This creates a Y-shaped configuration.
- **Mesenteric Defects Closure:** The spaces created by the rerouting of the bowel (mesenteric defects) are typically closed with sutures to prevent internal hernias.
- **Leak Test:** A leak test may be performed at the anastomoses.
- **Drain Placement (Optional):** A drain may be placed.
- **Closure:** Incisions are closed.

Postoperative Care:

- **Pain Management:** Opioid and non-opioid analgesics are used.
- **Fluid Management:** Patients typically start with sips of water and progress to clear liquids, then full liquids, puréed foods, and eventually solid foods over several weeks.
- **Mobility:** Early ambulation is encouraged to prevent deep vein thrombosis and pulmonary embolism.
- **Monitoring:** Close monitoring for complications like anastomotic leaks, bleeding, or infection.
- **Nutritional Supplementation**: Lifelong supplementation with vitamins and minerals (e.g., multivitamins, B12, iron, calcium, vitamin D) is crucial due to altered absorption, especially after RYGB.

• **Follow-up:** Regular follow-up appointments with the bariatric team (surgeon, dietitian, psychologist) are essential for monitoring weight loss, managing comorbidities, and addressing nutritional deficiencies.

Related Pathophysiology

Bariatric surgery induces weight loss and metabolic improvements through multiple mechanisms beyond simple caloric restriction or malabsorption.

- **Restrictive Effect:** Procedures like LSG physically limit the amount of food that can be consumed by reducing stomach volume, leading to early satiety.
- **Hormonal Changes:** This is a critical aspect, particularly for metabolic outcomes.
- **Ghrelin Reduction:** In LSG, the fundus of the stomach, which is the primary site of ghrelin (a hunger-stimulating hormone) production, is removed, leading to a significant reduction in ghrelin levels and decreased appetite [11].
- **GLP-1 and PYY Secretion:** Both SG and RYGB lead to rapid delivery of undigested nutrients to the distal small intestine (ileum and colon). This stimulates the release of gut hormones like Glucagon-Like Peptide-1 (GLP-1) and Peptide YY (PYY) [12]. GLP-1 enhances insulin secretion, slows gastric emptying, and promotes satiety, while PYY also promotes satiety and reduces food intake. These effects contribute significantly to improved glycemic control in T2DM.
- Changes in Bile Acid Metabolism: Bariatric surgery alters bile acid circulation, which plays a role in glucose and lipid metabolism, further contributing to metabolic improvements [13].
- Changes in Gut Microbiota: Alterations in the gut anatomy influence the composition and function of the gut microbiome. These changes are

increasingly recognized as contributing to improved metabolism and weight loss following surgery [14].

- Altered Food Preferences and Sensitivities: Patients often report changes in taste and preference for certain foods (e.g., reduced desire for fatty or sweet foods), which aids in sustained weight loss.
- Reduced Absorption (primarily with RYGB and BPD/DS): By bypassing a
 portion of the small intestine, the absorption of calories and nutrients is
 reduced. This is more pronounced in RYGB and even more so in BPD/DS.

These physiological changes collectively contribute to significant and sustained weight loss, as well as the remarkable remission or improvement of obesity-related comorbidities, especially Type 2 Diabetes Mellitus.

Complications and Management

Like any major surgery, bariatric procedures carry potential risks and complications, which can be acute or chronic.

Acute Complications (Early Postoperative Period):

- Anastomotic Leak: This is one of the most serious complications, occurring when there is a defect in a staple line or anastomosis, leading to leakage of gastric or intestinal contents into the abdominal cavity.
- **Management:** Requires prompt diagnosis (CT scan with oral contrast), often involving surgical re-intervention, endoscopic stenting, or percutaneous drainage.
- **Bleeding:** Can occur from staple lines, anastomoses, or port sites.
- **Management:** May require blood transfusions, endoscopic intervention, or surgical exploration.
- **Infection**: Wound infection, intra-abdominal abscess.

- **Management:** Antibiotics, drainage of abscesses.
- Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE): Blood clots forming in the legs that can travel to the lungs.
- **Management:** Prophylactic anticoagulation, early ambulation, compression devices. Treatment involves therapeutic anticoagulation.
- Anesthesia-Related Complications: Respiratory depression, cardiac events.
- Management: Standard anesthetic protocols and critical care support.

Chronic Complications (Late Postoperative Period):

- **Nutritional Deficiencies:** Common due to reduced intake and malabsorption.
- **Management:** Lifelong vitamin and mineral supplementation (multivitamin, B12, iron, calcium, vitamin D), regular monitoring of nutritional status.
- **Marginal Ulcers:** Ulcers at the gastrojejunostomy site after RYGB.
- **Management:** Proton pump inhibitors (PPIs), smoking cessation, avoidance of NSAIDs. In refractory cases, surgical revision.
- **Internal Hernia:** Bowel can herniate through mesenteric defects, causing obstruction. More common after RYGB.
- **Management:** Surgical repair, often emergent.
- **Bowel Obstruction:** Can occur due to adhesions, strictures, or internal hernias.
- **Management:** Conservative management (NG tube, IV fluids) initially; surgical intervention if conservative measures fail.

- **Gallstones:** Rapid weight loss increases the risk of gallstone formation.
- **Management:** Ursodiol may be prescribed prophylactically; cholecystectomy if symptomatic.
- **Dumping Syndrome:** Rapid emptying of food into the small intestine, leading to symptoms like nausea, vomiting, diarrhea, sweating, and dizziness. More common after RYGB.
- **Management:** Dietary modifications (small, frequent meals; avoid high-sugar foods; separate solids and liquids).
- **Strictures:** Narrowing of an anastomosis or staple line.
- Management: Endoscopic balloon dilation.
- **Weight Regain:** While many achieve significant weight loss, some experience weight regain over time.
- **Management:** Reinforcement of dietary and lifestyle changes, psychological support, pharmacotherapy, or revisional surgery in select cases.
- **Psychological Issues:** Depression, anxiety, body image issues.
- **Management:** Psychological counseling and support groups.

Outcomes and Prognosis

Bariatric surgery offers significant and durable weight loss and impressive metabolic outcomes, leading to improved quality of life and reduced mortality.

Short-Term Outcomes (1-2 years post-surgery):

• **Weight Loss:** Patients typically achieve 60-80% Excess Weight Loss (EWL) within the first 12-24 months. LSG generally results in 50-70% EWL, while LRYGB often achieves 60-80% EWL [15].

• Remission/Improvement of Comorbidities:

- Type 2 Diabetes Mellitus: Remission rates (HbA1c <6.5% without medication) are high, ranging from 60-80% after RYGB and 40-60% after SG, often occurring within days to weeks post-surgery, even before significant weight loss [16].</p>
- **Hypertension:** Improvement or remission in 50-70% of patients [16].
- Dyslipidemia: Improvement in lipid profiles in 70-80% of patients
 [16].
- **Obstructive Sleep Apnea**: Resolution or significant improvement in 70-90% of patients [16].
- NAFLD/NASH: Significant histological improvement or resolution in a large proportion of patients.
- Improved Quality of Life: Patients report significant improvements in physical function, self-esteem, and social interactions.

Long-Term Outcomes (5+ years post-surgery):

- **Sustained Weight Loss:** While some weight regain can occur, most patients maintain significant long-term weight loss (typically 50-60% EWL at 5-10 years) [17].
- **Durability of Comorbidity Remission:** The remission of T2DM and other comorbidities is often durable, though some patients may experience recurrence, especially with weight regain.
- **Reduced Mortality:** Bariatric surgery is associated with a significant reduction in overall mortality, particularly from cardiovascular disease,

diabetes, and cancer, compared to obese individuals who do not undergo surgery [18].

 Potential Long-Term Complications: As discussed in the "Complications" section, chronic issues like nutritional deficiencies, internal hernias, marginal ulcers, and bone health issues require ongoing monitoring and management.

Prognosis: The prognosis for individuals undergoing bariatric surgery is generally excellent, with substantial improvements in health, longevity, and quality of life. Success is maximized with adherence to postoperative dietary and lifestyle guidelines, lifelong nutritional supplementation, and regular follow-up with a multidisciplinary team.

Postoperative Care and Recommendations

Comprehensive and lifelong postoperative care is crucial for optimizing long-term outcomes and preventing complications after bariatric surgery.

• Dietary Progression:

- Clear Liquids (Day 1-2): Small sips of water, sugar-free clear liquids.
- Full Liquids (Weeks 1-2): Protein shakes, thinned puréed soups, sugar-free pudding.
- **Puréed Foods (Weeks 3-4):** Soft, mashed foods (e.g., scrambled eggs, cottage cheese, fish).
- Soft Foods (Weeks 5-8): Gradually introduce soft, easily chewable solid foods.
- Regular Diet (After 2-3 months): Emphasize lean protein, non-starchy vegetables, and whole grains. Avoid highly processed, sugary, and fatty foods.

• Key Principles:

- Small, frequent meals.
- Chew food thoroughly.
- Separate solids and liquids (drink 30 minutes before and after meals) to prevent dumping syndrome and ensure adequate protein intake.
- Prioritize protein intake to preserve lean muscle mass.
- Avoid carbonated beverages and straws.

• Physical Activity:

- **Early Ambulation:** Begin walking shortly after surgery to prevent blood clots.
- o **Gradual Increase:** Progressively increase activity levels.
- Regular Exercise: Aim for at least 30 minutes of moderate-intensity exercise most days of the week once cleared by the surgeon. This supports weight loss, improves body composition, and enhances overall health.

Medication:

- **Nutritional Supplements:** Lifelong daily intake of:
 - Multivitamin with minerals (iron, zinc, selenium).
 - Calcium citrate with Vitamin D.
 - Vitamin B12 (oral, sublingual, or injection, depending on the procedure and patient absorption).
 - Iron, especially for menstruating women and those with anemia.
- Medication Adjustments: Doses of medications for diabetes,
 hypertension, and dyslipidemia often need to be reduced or

- discontinued rapidly post-surgery. Close monitoring by a physician is essential.
- Avoid NSAIDs: Non-steroidal anti-inflammatory drugs (NSAIDs) should generally be avoided due to the increased risk of marginal ulcers.

Follow-up:

- Regular Appointments: Adherence to a structured follow-up schedule with the bariatric team (surgeon, dietitian, psychologist, primary care physician) is critical.
- Monitoring: Regular blood tests to monitor nutritional status (e.g., complete blood count, iron studies, B12, folate, vitamin D, calcium, albumin), kidney function, and liver function.
- Psychological Support: Continued psychological assessment and support to address eating behaviors, body image, and adjustment to significant lifestyle changes.
- **Support Groups:** Participation in bariatric surgery support groups can provide valuable peer support and education.

• Lifestyle Modifications:

- **Hydration:** Adequate fluid intake (at least 1.5-2 liters of non-caloric fluids daily).
- **Mindful Eating:** Pay attention to hunger and fullness cues, eat slowly, and savor meals.
- Stress Management: Develop healthy coping mechanisms for stress.
- **Alcohol:** Limit or avoid alcohol consumption, as tolerance can change and absorption may be altered.

Recent Innovations and Advances

This section could delve into newer techniques and technologies. Recent innovations in bariatric surgery are largely focused on enhancing safety, minimizing invasiveness, improving precision, and expanding the range of effective interventions.

• Minimally Invasive Techniques (Laparoscopic and Robotic Surgery):

- Laparoscopic Surgery: This has become the standard for most bariatric procedures. It involves small incisions, leading to less pain, reduced scarring, shorter hospital stays, and faster recovery compared to traditional open surgery [19].
- o Robotic-Assisted Surgery: The integration of robotic systems (e.g., da Vinci Surgical System) offers surgeons enhanced precision, dexterity, and 3D visualization. This allows for more complex maneuvers with greater accuracy, potentially reducing complications and tissue trauma, and facilitating a quicker recovery [19, 20]. While sometimes associated with slightly longer operative times and higher costs, robotic surgery has demonstrated benefits in terms of reduced bleeding, transfusions, and infections in certain procedures, especially revisional surgeries [21].
- Endoscopic Bariatric Procedures (EBTs): These non-surgical, incision-free procedures are performed using an endoscope inserted through the mouth.
 - Endoscopic Sleeve Gastroplasty (ESG): Stitches are placed internally to reduce the size of the stomach, mimicking the restrictive effect of a surgical sleeve without external incisions or tissue resection. ESG offers benefits like no visible scars, outpatient or same-day procedures, and faster recovery [19].

- o **Intragastric Balloons (IGBs):** Silicone balloons are temporarily placed in the stomach and inflated to create a feeling of fullness, reducing food intake. These are non-surgical, reversible, and typically do not require hospitalization, making them an option for temporary weight loss or as a bridge to surgery for high-risk patients [19, 22].
- EndoBarrier: A device that lines a portion of the small intestine to prevent nutrient absorption, showing promise in improving glycemic control in T2DM [19].

Newer Surgical Techniques:

- Single Anastomosis Duodeno-Ileal Switch (SADI-S): This is a modification of the traditional biliopancreatic diversion with duodenal switch, combining a sleeve gastrectomy with a single anastomosis connecting the duodenum to a more distal segment of the ileum. It aims to simplify the procedure while maintaining excellent weight loss and metabolic outcomes, particularly for T2DM [23].
- One Anastomosis Gastric Bypass (OAGB) / Mini-Gastric Bypass (MGB): This procedure involves creating a long, narrow gastric pouch and connecting it to a loop of small intestine with a single anastomosis. It is gaining popularity due to its simplicity, shorter operative time, and comparable efficacy to RYGB for weight loss and T2DM remission [24].
- Enhanced Recovery After Surgery (ERAS) Protocols: These multidisciplinary protocols optimize patient care pathways before, during, and after surgery to accelerate recovery, reduce complications, and shorten hospital stays. Components include preoperative counseling, optimized pain management, early mobilization, and tailored nutritional

plans [19].

- **Personalized Bariatric Surgery:** The trend is towards tailoring surgical approaches to individual patient needs, considering factors like BMI, comorbidities, lifestyle, and genetic predispositions, to maximize safety and long-term success [19].
- **Pharmacotherapy Integration:** The emergence of highly effective GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has opened new avenues. These medications are sometimes used pre-operatively to induce initial weight loss and improve surgical candidacy, or post-operatively to augment weight loss or manage weight regain. Research is ongoing to determine optimal integration strategies [25].

These innovations reflect a continuous effort to make bariatric surgery safer, more accessible, and more effective in addressing the complex disease of obesity and its metabolic consequences.

Case Studies or Clinical Examples

Given the scope of this request, I will outline what such a section would include rather than creating specific patient cases.

This section would present anonymized clinical cases to illustrate the application of different bariatric procedures and their outcomes. Each case study would typically include:

- **Patient Demographics:** Age, gender, BMI, relevant medical history.
- Presenting Symptoms/Comorbidities: Details of obesity-related conditions.

- **Preoperative Assessment:** Summary of multidisciplinary evaluation, including psychological and nutritional findings.
- **Procedure Chosen and Rationale:** Explanation of why a particular surgical procedure (e.g., SG, RYGB, OAGB) was selected for this patient.
- **Surgical Course:** Brief description of the surgical procedure and any intraoperative findings.
- **Postoperative Course:** Immediate recovery, initial weight loss, and management of any early complications.

Outcomes:

- **Weight Loss Trajectory:** Weight loss at various time points (e.g., 6 months, 1 year, 3 years).
- **Comorbidity Resolution/Improvement:** Changes in diabetes status, blood pressure, lipid profile, sleep apnea, etc.
- Quality of Life Changes: Reported improvements in physical activity, mood, and social functioning.
- Challenges and Management: Any long-term complications, nutritional deficiencies, or weight regain, and how they were addressed.
- **Lessons Learned:** A concluding statement highlighting key takeaways from the case.

Example Case Study Template (Conceptual):

Case Study 1: Remission of Type 2 Diabetes after Roux-en-Y Gastric Bypass

• **Patient:** Ms. A, 48-year-old female, BMI 42 kg/m\$^2\$ with T2DM (HbA1c 9.2% on multiple medications), hypertension, and obstructive sleep apnea.

- **Preoperative:** Struggled with weight for decades, failed multiple diets. Psychological evaluation revealed readiness for lifestyle changes.
- **Procedure:** Laparoscopic Roux-en-Y Gastric Bypass (LRYGB).
- **Postoperative:** Discharged on post-op day 2. Rapid cessation of insulin and most oral diabetes medications within weeks.

Outcomes:

- 1 year: 75% EWL. HbA1c 5.5% without medication (diabetes remission). Hypertension controlled with a single medication. Sleep apnea resolved.
- 5 years: Maintained 68% EWL. Continued diabetes remission.
 Requires lifelong B12 and iron supplementation. Experienced mild dumping syndrome managed with diet.
- **Lessons:** Illustrates the powerful metabolic effects of RYGB on T2DM remission, often independent of massive weight loss.

Case Study 2: Successful Weight Management with Sleeve Gastrectomy

- **Patient:** Mr. B, 35-year-old male, BMI 46 kg/m\$^2\$, no significant comorbidities apart from severe obesity.
- **Preoperative:** Active lifestyle hindered by weight. No significant psychological issues.
- **Procedure:** Laparoscopic Sleeve Gastrectomy (LSG).
- **Postoperative:** Smooth recovery. Tolerated dietary progression well.

Outcomes:

• 1 year: 60% EWL. Significant improvement in mobility and energy levels.

- 3 years: Maintained 55% EWL. Occasional mild reflux managed with
 PPI. No nutritional deficiencies with consistent supplementation.
- Lessons: Highlights LSG as an effective and safe procedure for patients primarily seeking significant weight loss without extensive malabsorptive considerations, while noting potential for GERD.

References

- World Health Organization. Obesity and overweight fact sheet. 2024 May
 Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
- Newsweek. Map Reveals How Obesity Rates in the U.S Compares to Europe. 2025 Feb 22. Available from: https://www.newsweek.com/map-reveals-obesity-rates-us-compares-europe-2034188
- 3. Pichler M, et al. Obesity Prevalence in the Long-Term Future in 18 European Countries and in the USA. Obes Facts. 2020 Nov 17;13(5):655-667.
- 4. World Health Organization. WHO European Regional Obesity Report 2022. Copenhagen: WHO Regional Office for Europe; 2022. Available from: https://apps.who.int/iris/handle/10665/353747
- 5. World Obesity Federation. Global Obesity Observatory: Ranking (% obesity by country). [cited 2025 Jun 6]. Available from: https://data.worldobesity.org/rankings/
- 6. Zaky OSB. Weight Loss Surgery Cost. Compare Prices and Options. Medical Solutions Barcelona. 2021 Jun 28. Available from: https://www.medical-solutions-bcn.com/en/blog/weight-loss-surgery-prices/
- 7. Angrisani L, et al. IFSO Worldwide Survey 2020–2021: Current Trends for Bariatric and Metabolic Procedures. Obes Surg. 2024 Mar 4;34(5):1-14.

- 8. American Society for Metabolic and Bariatric Surgery. Estimate of Bariatric Surgery Numbers, 2011-2023. [cited 2025 Jun 6]. Available from: https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers/
- 9. GlobeNewswire. Global Bariatric Surgeries Market to Hit USD 27.64 Billion by 2030, Fueled by Rising Demand for Minimally Invasive Techniques The Insight Partners. 2025 Apr 1. Available from: https://www.globenewswire.com/news-release/2025/04/01/3053545/0/en/Global-Bariatric-Surgeries-Market-to-Hit-USD-27-64-Billion-by-2/030-Fueled-by-Rising-Demand-for-Minimally-Invasive-Techniques-The-Insight-Partners.html
- 10. Nordbariatric Clinic. Infographics: Bariatric Surgery Trends in Europe and the US. [cited 2025 Jun 6]. Available from: https://www.nordbariatric.com/en/articles/infographics-obesity-surgery-statistics/
- 11. Mechanick JI, et al. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Surgery—2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Endocr Pract. 2019 Nov;25(11):1-70.
- 12. Rubino F, et al. Metabolic surgery in the treatment of type 2 diabetes mellitus: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2020 Jan 1;105(1):1-26.
- 13. Lazar S, et al. The role of bile acids in the metabolic improvements after bariatric surgery. Obes Rev. 2021 Sep;22(9):e13303.
- 14. Valdes AM, et al. Role of the gut microbiota in bariatric surgery and its associated weight loss. Gut. 2020 Feb;69(2):373-383.

- 15. Arterburn DE, et al. Comparative effectiveness of bariatric surgery and nonsurgical therapy for obesity in patients with and without type 2 diabetes. Ann Intern Med. 2015 Mar 17;162(5):346-55.
- 16. Sjöström L, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007 Aug 23;357(8):741-52.
- 17. Maciejewski ML, et al. Association of bariatric surgery with long-term cardiovascular outcomes and all-cause mortality among adults with and without type 2 diabetes. JAMA. 2020 Jan 28;323(4):307-317.
- 18. Adams TD, et al. Health outcomes of gastric bypass surgery compared with nonsurgical control subjects. N Engl J Med. 2017 Sep 21;377(12):1143-1155.
- 19. Luna R. Trends in Bariatric Surgery Techniques in 2025. Dr Ruben Luna.
 [cited 2025 Jun 6]. Available from:
 https://drrubenluna.com/trends-in-bariatric-surgery-techniques-in-202
 5/
- 20. Continental Hospitals. Key Innovations in Bariatric Surgery. 2025 Apr 15.

 Available from:

 https://continentalhospitals.com/blog/key-innovations-in-bariatric-surgery/
- 21. Lopez-Correa J, et al. Advancements in Bariatric Surgery: A Comparative Review of Laparoscopic and Robotic Techniques. J Clin Med. 2025 Feb 8;14(2):151.
- 22. NObesity. Revolutionary Advances In Bariatric Surgery Technology: What's Next? 2024 Oct 18. Available from: https://nobesity.in/revolutionary-advances-in-bariatric-surgery-technology-whats-next/
- 23. Mission Surgical Clinic. Innovations in Bariatric Surgery: What's New and Effective. 2024 Jun 20. Available from: https://www.missionsurgical.com/blogs/innovations-in-bariatric-surgery-whats-new/

- 24. Zhang S, et al. Recent advancements in bariatric/metabolic surgery. J Biomed Res. 2015 Nov 1;29(6):449-456.
- 25. American Society for Metabolic and Bariatric Surgery. Bariatric Surgery

 More Effective and Durable Than New Obesity Drugs and Lifestyle
 Intervention. 2024 Jun 11. Available from:

 https://asmbs.org/news-releases/bariatric-surgery-more-effective-and-durable-than-new-obesity-drugs-and-lifestyle-intervention/